Liquid biopsy allows the detection of various cancer types through a simple blood draw. It identifies and evaluates fragments of DNA released by tumor cells into the bloodstream. These DNA fragments provide insights about any genetic mutations occurring in the tumor. Liquid biopsy provides a simple and non-invasive alternative to surgical tumor biopsies. It assists physicians in screening, diagnosing, and monitoring cancer without requiring invasive procedures.

The global Liquid Biopsy Market is estimated to be valued at US$ 5.25 billion in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The key opportunity driving the growth of the liquid biopsy market is its ability to provide non-invasive cancer screening. Traditional biopsy methods involve surgical removal of tumor tissues which can cause significant discomfort and complications to patients. Liquid biopsy overcomes this challenge by using blood samples for cancer screening and monitoring. Its non-invasive nature makes it suitable for regular screening of at-risk patients. This increases compliance for cancer screening programs. With advancement in technology, liquid biopsy is demonstrating high accuracy in detecting early-stage cancers. Its wide application in screening asymptomatic patients contributes hugely to early disease diagnosis. As it reduces health risks associated with surgery, liquid biopsy is expected to gain more acceptance among cancer patients as well as physicians. This growing preference for simple and safe screening processes will upsurge the demand for liquid biopsy testing over the forecast period.

Porter's Analysis

Threat of new entrants: The threat of new entrants is moderate as the liquid biopsy industry requires large capital investments and established distribution channels. However, the market is growing rapidly attracting new players.

Bargaining power of buyers: The bargaining power of buyers is high since liquid biopsy tests are not mandatory. Buyers can choose alternative cancer screening methods or therapies based on pricing and utility.

Bargaining power of suppliers: The power of suppliers is moderate since most companies operate integrated models and are not dependent on a single technology provider. Suppliers of analysis platforms and kits have some pricing power.

Threat of new substitutes: The threat of substitutes is moderate as alternative cancer screening and diagnostic methods exist. However, liquid biopsy offers less invasive testing and real-time monitoring benefits over tissue biopsies.

Competitive rivalry: The competitive rivalry is high due to large number of established global players and new entrants. Companies compete based on analytical and clinical validity, turnaround times, ease of use and total cost of testing.

SWOT Analysis

Strength: Liquid biopsy harvests blood samples non-invasively instead of tissue biopsies to detect cancer DNA and enable blood tests to be conducted repeatedly. This drives increased patient acceptance and uptake.

Weakness: Analytical validity and clinical utility of tests varies by company and platform. Regulatory standards and reimbursement policies are still evolving. Cost of liquid biopsy is higher than traditional diagnostics.

Opportunity: Rapid adoption in clinical cancer management helps reduce healthcare costs associated with inaccurate diagnostic procedures. Growing applications in treatment selection and recurrence monitoring present a large commercial opportunity.

Threats: Established biopsy and imaging methods continue to be preferred in certain cancer types and lines of treatment. Ethical and legal issues related to incidental findings could hamper market growth.

Key Takeaways

The Global Liquid Biopsy Market Size  is expected to witness high growth at a CAGR of 6.7% during the forecast period of 2023 to 2030. The market size reached US$ 5.25 Bn in 2024 and is anticipated to exceed US$ 10 Bn by 2030.

North America dominates the global liquid biopsy market currently due to presence of leading players, rising cancer incidence and availability of advanced healthcare systems. The Asia Pacific region is projected to grow at the fastest pace during the forecast period with increasing healthcare spending, expanding private hospital network and rising public awareness in China, India and Japan.

Key players operating in the liquid biopsy market are Guardant Health, F. Hoffmann-La Roche AG, bioMérieux SA, Myriad Genetics, Thermo Fisher Scientific Inc, Qiagen N.V., Menarini Silicon Biosystems, Illumina, Inc and GRAIL. These players focus on new product launches, partnerships, acquisitions and geographical expansion strategies to gain market share and access new customer segments.

For More details on the topic:
https://www.dailyprbulletin.com/liquid-biopsy-market-market-size-share-analysis-growth/
 
Check more trending articles related to this topic:
 
https://careersplay.com/halal-food-gastronomy-weaving-stories-of-culture-community-and-culinary-bliss